Literature DB >> 19939747

Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients.

C R Hansen1, T Pressler, K G Nielsen, P Ø Jensen, T Bjarnsholt, N Høiby.   

Abstract

BACKGROUND: Achromobacter xylosoxidans infection may cause conspicuous chronic pulmonary inflammation in cystic fibrosis (CF) patients similar to Pseudomonas aeruginosa and the Burkholderia cepacia complex (Bcc). Evolution in lung function was compared in chronically infected patients. Cytokine concentrations in CF patients with and without chronic infection were compared to healthy controls.
METHODS: Cytokines in serum and sputum were measured using multiplex bead based immunoassay.
RESULTS: Sixty CF patients, 11 with A. xylosoxidans, 11 with Bcc, 21 with P. aeruginosa and 17 non-infected CF patients were compared to 11 healthy controls. A. xylosoxidans patients were younger, but had a FEV(1) decline similar to P. aeruginosa patients. Bcc patients had the steepest decline in FEV(1). Serum levels of G-CSF, IL-6 and TNF-alpha were significantly higher in CF patients compared to healthy controls. Chronically infected CF patients had significantly higher serum levels of IFN-gamma and IL-6 compared to non-infected CF patients. Bcc patients had significantly lower serum G-CSF and A. xylosoxidans patients had significantly higher sputum TNF-alpha compared to the other groups of chronically infected patients.
CONCLUSION: A. xylosoxidans can cause a level of inflammation similar to P. aeruginosa in chronically infected CF patients. A. xylosoxidans is a clinically important pathogen in CF and should be treated accordingly.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19939747     DOI: 10.1016/j.jcf.2009.10.005

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  53 in total

1.  First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM.

Authors:  Julien Bador; Lucie Amoureux; Jean-Marie Duez; Anthony Drabowicz; Eliane Siebor; Catherine Llanes; Catherine Neuwirth
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

Review 2.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

3.  Achromobacter xylosoxidans Cellular Pathology Is Correlated with Activation of a Type III Secretion System.

Authors:  Adam M Pickrum; Orlando DeLeon; Aaron Dirck; Maxx H Tessmer; Molly O Riegert; Julie A Biller; Nathan A Ledeboer; John R Kirby; Dara W Frank
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

4.  Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.

Authors:  B D Edwards; J Greysson-Wong; R Somayaji; B Waddell; F J Whelan; D G Storey; H R Rabin; M G Surette; M D Parkins
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

5.  Polymorphonuclear leukocytes restrict growth of Pseudomonas aeruginosa in the lungs of cystic fibrosis patients.

Authors:  Kasper N Kragh; Morten Alhede; Peter Ø Jensen; Claus Moser; Thomas Scheike; Carsten S Jacobsen; Steen Seier Poulsen; Steffen Robert Eickhardt-Sørensen; Hannah Trøstrup; Lars Christoffersen; Hans-Petter Hougen; Lars F Rickelt; Michael Kühl; Niels Høiby; Thomas Bjarnsholt
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

6.  Role of AxyZ Transcriptional Regulator in Overproduction of AxyXY-OprZ Multidrug Efflux System in Achromobacter Species Mutants Selected by Tobramycin.

Authors:  Julien Bador; Catherine Neuwirth; Nadège Grangier; Marie Muniz; Leslie Germé; Jérémy Bonnet; Vignesh-Guru Pillay; Catherine Llanes; Claire de Curraize; Lucie Amoureux
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

7.  Impact of High Diversity of Achromobacter Populations within Cystic Fibrosis Sputum Samples on Antimicrobial Susceptibility Testing.

Authors:  Chloé Dupont; Estelle Jumas-Bilak; Anne-Laure Michon; Raphaël Chiron; Hélène Marchandin
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

8.  Molecular characterization of Achromobacter isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid, Spain.

Authors:  Laura Barrado; Patricia Brañas; M Ángeles Orellana; M Teresa Martínez; Gloria García; Joaquín R Otero; Fernando Chaves
Journal:  J Clin Microbiol       Date:  2013-03-27       Impact factor: 5.948

9.  Distribution of allelic variants of the chromosomal gene bla OXA-114-like in Achromobacter xylosoxidans clinical isolates.

Authors:  German Matías Traglia; Marisa Almuzara; Andrea Karina Merkier; Mariana Papalia; Laura Galanternik; Marcela Radice; Carlos Vay; Daniela Centrón; María Soledad Ramírez
Journal:  Curr Microbiol       Date:  2013-06-15       Impact factor: 2.188

10.  Presence of OXA-type enzymes in Achromobacter insuavis and A. dolens.

Authors:  German Traglia; Mariana Papalia; Marisa Almuzara; Gabriel Gutkind; Daniela Centrón; Carlos Vay; Marcela Radice; María Soledad Ramírez
Journal:  Curr Microbiol       Date:  2014-06-04       Impact factor: 2.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.